Sinclair Pharma Regulatory News (SPH)

Sinclair Pharma plc

TOTAL ISSUED SHARE CAPITAL

London, 30 September 2016 Sinclair Pharma plc (SPH.L), ("Sinclair" or the "Company"): In accordance with the requirements of the FCA's Disclosure and Transparency Rule 5.6.1, Sinclair confirms that the Company's issued share capital consists of 502,089,508 ordinary shares of 1p each in issue, each with equal voting rights. No shares are held in treasury.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure and Transparency Rules.

For further information, please contact:

Sinclair Pharma plc Tel: +44 (0) 20 7467 6920

Chris Spooner

Alan Olby

Andy Crane

Peel Hunt LLP (Nominated Adviser) Tel: +44 (0) 20 7418 8900

James Steel

Oliver Jackson

Notes to Editors:

About Sinclair Pharma plc 

Sinclair Pharma plc is an international company operating in the fast growth, high gross margin, global aesthetics market. Sinclair has built a strong portfolio of differentiated, complementary aesthetics technologies, which are experiencing significant growth, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments. The Company is planning entry to multiple new geographic markets and line extension launches over the next few years. Sinclair has an established sales and marketing presence in the leading EU markets and Brazil, and a network of international distributors. For more information, please visit www.sinclairpharma.com